The NIH has awarded $1.3 million to UMass Amherst’s Chang Liu to develop an at-home HIV test with lab-comparable sensitivity, aiming to improve early diagnosis and address diagnostic barriers in resource-limited settings.
IntelliGenome receives regulatory clearance and partners with Velez Lab for distribution of its molecular diagnostic assay.
Co-Diagnostics has completed its assay development strategy for Bundibugyo virus, following the WHO’s emergency declaration and CDC’s updated traveler screening measures amid ongoing Ebola outbreaks in the DRC and Uganda.
A field-deployable test demonstrates high sensitivity in identifying low-level infections that traditional methods miss, potentially supporting elimination efforts.
The high-throughput host-response assay provides results in approximately 20 minutes to help guide treatment decisions and antimicrobial stewardship.
The PCR test detects 11 bacterial, viral, and parasitic pathogens from a stool sample in approximately 74 minutes.
Research identifies how circulating tumor DNA can inform personalized treatment and surveillance strategies.